Lumos Diagnostics Holdings Ltd. LDX

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has received a US$767,800 purchase order for its FebriDx® rapid diagnostic test from US distribution partner PHASE Scientific, marking further progress in the product’s commercial rollout. The order will be fulfilled progressively through...

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has expanded the European commercial footprint of its FebriDx rapid diagnostic test after signing an exclusive distribution agreement with Romanian healthcare supplier Alpha Medical. Under the agreement, Alpha Medical will manage sales,...

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) finished the fourth quarter of FY26 with strong full-year growth from its flagship FebriDx® rapid diagnostic test, expanding US commercial adoption and closing the period with US$15.4 million in cash. Unaudited FY26 revenue increased 6% on...

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has secured the rollout of its FebriDx rapid diagnostic test across more than 30 US urgent care sites and advanced three additional major healthcare groups, representing more than 230 sites, into clinical and economic validation. Together,...

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has received a A$709,837 cash refund under the Australian Government’s Research and Development Tax Incentive, strengthening its capacity to advance its rapid point-of-care diagnostic technology platforms. The refund relates to eligible...

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has reported encouraging early progress in the US commercial rollout of its FebriDx® rapid respiratory infection test following recent FDA CLIA waiver clearance, with reimbursement performance and customer adoption tracking positively ahead of...

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has completed a further milestone under its BARDA-funded FebriDx® paediatric clinical study, enrolling 250 patients in the trial. The achievement marks milestone number 7 under the company’s agreement with the Biomedical Advanced Research...

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has received a further milestone payment of just over US$500,000 from the US Biomedical Advanced Research and Development Authority (BARDA) after securing CLIA waiver status for its FebriDx® rapid respiratory infection test, adding fresh...

Trump warned the US would step up strikes on Iran over the next two to three weeks